|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-12-14
|
|
pubmed:abstractText |
The aim of this study was to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) of combination therapy with gemcitabine and S-1 in patients with advanced pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
421-7
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16319514-Adult,
pubmed-meshheading:16319514-Aged,
pubmed-meshheading:16319514-Antimetabolites, Antineoplastic,
pubmed-meshheading:16319514-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16319514-Deoxycytidine,
pubmed-meshheading:16319514-Disease Progression,
pubmed-meshheading:16319514-Drug Combinations,
pubmed-meshheading:16319514-Female,
pubmed-meshheading:16319514-Humans,
pubmed-meshheading:16319514-Infusions, Intravenous,
pubmed-meshheading:16319514-Male,
pubmed-meshheading:16319514-Maximum Tolerated Dose,
pubmed-meshheading:16319514-Middle Aged,
pubmed-meshheading:16319514-Neoplasm Metastasis,
pubmed-meshheading:16319514-Oxonic Acid,
pubmed-meshheading:16319514-Pancreatic Neoplasms,
pubmed-meshheading:16319514-Prognosis,
pubmed-meshheading:16319514-Pyridines,
pubmed-meshheading:16319514-Tegafur,
pubmed-meshheading:16319514-Time Factors,
pubmed-meshheading:16319514-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
|
|
pubmed:affiliation |
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan. hiueno@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
